RE:Aeterna near term revenues?lscfa wrote: Sales of Macrilen® (macimorelin) are temporarily discontinued in the United States commercial market for the diagnosis of adult growth hormone deficiency ("AGHD"), until anticipated re-launch with an alternate commercialization partner. Aeterna has an ongoing effort to identify strategic development and commercialization partner.
Novo Nordisk launched the product for the adult market. It's been slow. The most important market is children. Growth hormone matters in children alot more than in adults for obvious reasons. The pediatric trial is almost complete now. Novo Nordisk plunked down $145 million for this opportunity before. What will the terms of a new licensing deal for North American rights be with the completion of the pediatric trial soon for the growth hormone test. Gilles must like how negotiations for a new deal are progressing. CZO could even sell the asset. With the pediatric trial completed it could license and simply collect royalties.
According to AEZS the pediatric market is similar in size to the currently approved adult market but the awareness/need is greater to determine growth hormone deficiency in children. Growth hormone deficiency has significant implications for children's development. 16:50 Virtual Investor: Ask The CEO: Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) - Zoom prophetoffactz wrote:That test which now appears to be in the process of re-licensing with a potential near-term approval of a pediatric indication is the ONLY approved test specifically for growth hormone deficiency in adults. It is approved by the FDA and in Europe. Gilles could have a good appreciation of the relicensing discussions.
------
August 29, 2022 12:35 PM EDTUpdated September 2, 08:31 AM R&D
Four years and $145M+ later, Novo Nordisk hands back the rights to hormone growth deficiency test
Nicole DeFeudis
Editor
After changing hands a couple of times, Aeterna Zentaris’ adult growth hormone deficiency (AGHD) test Macrilen is returning to its original developer as Novo Nordisk forfeits the rights.
Aeterna announced on Monday that the Danish pharma is returning the US and Canada rights, just four years after plunking down $145 million plus tiered royalties and an equity investment worth more than $36 million to secure the oral ghrelin agonist.